Lincoln Pharma. (LINCOLN)

FairStock Score: 50/100 — MIXED

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Zero-debt balance sheet with D/E of 0.00 provides strong downside protection.
• Decent capital efficiency with ROE of 13.74% and ROCE of 17.28%.
• Profit growth of 37.70% with a PEG of 0.56 suggests attractive value for growth.
• Promoter holding of 49.78% aligns management interests with minority shareholders.
• Piotroski F-Score of 7/9 indicates sound financial health.

Concerns

• Dividend yield of only 0.29% offers negligible income cushion.
• Profit growth far exceeds sales growth, which may be unsustainable without revenue acceleration.
• FairStock Score of 53/100 suggests mixed business quality and momentum.
• At P/B of 1.89, it is not a deep-value asset play.

AI Analysis

At ₹611.45, Lincoln Pharma has a market cap of ₹1,264 Cr and a P/E of 14.39. This is not a classic Graham net-net, but it has traits I admire. The balance sheet is spotless — no debt at all, with a book value of ₹322.75, so a P/B of 1.89 is acceptable for a business earning 13.74% on equity. The ROCE of 17.28% tells me capital is being put to sensible use. With promoters holding 49.78%, their interests are aligned with mine. What attracts me is the earnings trajectory. Sales grew 13.49%, but profit jumped 37.70%, and the latest quarter delivered ₹166 Cr sales and ₹29 Cr net profit. A PEG of 0.56, based on that profit growth, makes the valuation look reasonable. The Piotroski score of 7/9 reinforces the health of the underlying financials. At 14 times earnings, the market is not overpaying. Still, I need caution. The dividend yield is negligible, so my return must come from business compounding, not income. The profit growth is far ahead of revenue growth; that could mean operating leverage, but I want to see sales accelerate or margins hold before I call it a moat. The FairStock score of 53 is mixed, and the stock sits well below its 52-week high of ₹770, reminding me that volatility is real. My approach is to buy a wonderful business at a fair price. Lincoln Pharma looks like a promising fast grower with a clean balance sheet and decent economics, but I would keep monitoring quarterly sales and margin stability before making a full commitment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer